Nigella Sativa Oil for Eczematous Otitis Externa

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBezmialem Vakif University

About this trial

Eczematous otitis externa is a common inflammatory condition of the external auditory canal characterized by itching, discomfort, discharge, and pain. Topical corticosteroids are widely used for treatment; however, alternative therapies with fewer side effects are of increasing interest.

This study aims to compare the efficacy of Nigella sativa (black seed) oil and mometasone furoate ear drops in the treatment of eczematous otitis externa. Nigella sativa is a natural product with known anti-inflammatory and antimicrobial properties.

In this randomized, controlled clinical trial, adult patients with eczematous otitis externa will be assigned to receive either Nigella sativa oil or mometasone furoate ear drops for 10 days. Clinical symptoms and inflammatory findings will be evaluated at baseline and after treatment.

The objective of this study is to determine whether Nigella sativa oil is an effective and safe alternative to topical corticosteroid therapy.

Eligibility criteria

Qualifiers

Adult patients aged 18 years and older

Clinical diagnosis of eczematous otitis externa confirmed by otoscopic examination

Presence of at least one symptom related to the affected ear (itching, discomfort, otorrhea, or pain)

Willingness to participate and ability to provide written informed consent

Disqualifiers

Known hypersensitivity or allergic reaction to Nigella sativa oil or mometasone furoate

Use of topical or systemic corticosteroids or other ear medications within a defined period prior to enrollment

Presence of acute otitis externa of infectious origin requiring antibiotic treatment

History of ear surgery or structural abnormalities of the external auditory canal

Trial design

Treatments tested in this trial

  • Mometasone Furoate (MF)
  • Nigella sativa oil

Treatment groups

85 Participants
are divided into 2 treatment groups

Sponsors and collaborators